Drug Trial News

RSS

Clinical trial reveals dapagliflozin's impact on heart failure and type 2 diabetes management

Researchers conducted a clinical trial on the effects of dapagliflozin on the urinary albumin-to-creatinine ratio (UACR) in patients with heart failure (HF) and type 2 diabetes mellitus (T2D).

29 Nov 2023

Study finds promising new approach to treating locally advanced pancreatic cancer

A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective in patients with locally advanced pancreatic cancer, yielding a higher progression-free survival (PFS) and overall response rate (ORR).

28 Nov 2023

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)-;two related blood diseases that disproportionally strike older adults-;are notoriously difficult to treat and associated with high relapse rates.

28 Nov 2023

Abiomed announces enrollment of first patient in landmark RECOVER IV trial for AMI cardiogenic shock

Abiomed, part of Johnson & Johnson MedTech, announces the first patient in the world has been enrolled in the landmark RECOVER IV randomized controlled trial (RCT).

27 Nov 2023

Drug for children with achondroplasia may help reduce chances of SIDS

A drug that boosts bone growth in children with the most common form of dwarfism, may also reduce their chances of sudden infant death syndrome, sleep apnea and needing surgery, according to a new study.

21 Nov 2023

Immunotherapy drug is safe and may benefit overall survival for patients with advanced NSCLC

For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new eClinicalMedicine study by UPMC Hillman Cancer Center researchers.

21 Nov 2023

Novel antidepressant zuranolone effective in alleviating depression and anxiety symptoms

The efficacy and safety of zuranolone in treating major depressive disorder (MDD).

20 Nov 2023

Breakthrough in tuberculosis treatment: TB-PRACTECAL trial reveals efficacy of new oral regimen

The TB-PRACTECAL clinical trial outcomes, which evaluated the efficacy and safety of oral bedaquiline.

20 Nov 2023

Oral antibiotic taken once-daily for six months reduces risk of developing drug-resistant TB

Two landmark clinical trials reported today at the Union meeting showed that an oral antibiotic taken for six months once-daily substantially reduced the risk of developing drug-resistant TB.

16 Nov 2023

Autoimmune rheumatic disease patients benefit significantly from fourth COVID-19 vaccine dose

Patients with autoimmune rheumatic diseases, which include rheumatoid arthritis and other chronic disorders that cause inflammation, are at increased risk of SARS-CoV-2 infection, as well as death due to severe COVID-19.

15 Nov 2023

Major trial finds apixaban reduces stroke risk in patients with device-detected atrial fibrillation

The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, a global study has found.

13 Nov 2023

Recaticimab injection every 1-3 months may safely lower bad cholesterol

A new PCSK9 inhibitor (recaticimab) injected every one to three months may work safely and provide more flexible dosing to lower cholesterol, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Abelacimab significantly reduces bleeding risk in atrial fibrillation patients with stroke risk

An experimental anti-clotting medication, abelacimab, significantly reduced bleeding among people with atrial fibrillation (or AFib) who were at risk of stroke, according to results of the AZALEA-TIMI 71 trial, presented today as late-breaking science at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

New drug zilebesiran effectively lowers blood pressure for six months, study finds

A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 of the KARDIA study, reported as late-breaking science today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Single injection of new medication effectively eliminates Lp(a) for nearly one year

In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.

13 Nov 2023

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).

13 Nov 2023

Clinical trial underway for novel human milk-based microbiome therapy

In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation.

10 Nov 2023

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab-;an antibody that targets a protein expressed on certain immune cells-;was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the autoimmune disease lupus.

10 Nov 2023

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

In this groundbreaking study, researchers developed a mucosal adenoviral-vector vaccine, ChAd-SARS-CoV-2-S, which demonstrated sustained and robust immunity against a challenging Omicron variant in nonhuman primates, indicating a promising direction for durable COVID-19 protection strategies. Unlike traditional intramuscular vaccines, this mucosal vaccine elicited a comprehensive immune response, potentially paving the way for more effective and long-lasting COVID-19 vaccines.

9 Nov 2023

Drug Trial News

Clinical trial reveals dapagliflozin's impact on heart failure and type 2 diabetes management

Study finds promising new approach to treating locally advanced pancreatic cancer

FDA awards grant for phase 1 clinical trial of experimental AML/MDS treatment

Abiomed announces enrollment of first patient in landmark RECOVER IV trial for AMI cardiogenic shock

Drug for children with achondroplasia may help reduce chances of SIDS

Immunotherapy drug is safe and may benefit overall survival for patients with advanced NSCLC

Novel antidepressant zuranolone effective in alleviating depression and anxiety symptoms

Breakthrough in tuberculosis treatment: TB-PRACTECAL trial reveals efficacy of new oral regimen

Oral antibiotic taken once-daily for six months reduces risk of developing drug-resistant TB

Autoimmune rheumatic disease patients benefit significantly from fourth COVID-19 vaccine dose

Major trial finds apixaban reduces stroke risk in patients with device-detected atrial fibrillation

Recaticimab injection every 1-3 months may safely lower bad cholesterol

Abelacimab significantly reduces bleeding risk in atrial fibrillation patients with stroke risk

New drug zilebesiran effectively lowers blood pressure for six months, study finds

Single injection of new medication effectively eliminates Lp(a) for nearly one year

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

Clinical trial underway for novel human milk-based microbiome therapy

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

Mucosal vaccine shows lasting defense against SARS-CoV-2 Omicron in primate study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News